Esophagogastric Junction Disorder
8
1
1
2
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
12.5%
1 terminated out of 8 trials
66.7%
-19.9% vs benchmark
13%
1 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (8)
Savolitinib for Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma Patients
Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer
Role of EndoFLIP in the Diagnostic Paradigm of Esophagogastric Junction Outflow Obstruction
CIRCULATing Biomarkers for Individualized Surgical Therapy in gastroEsophageal Cancer - Phase 1
Evaluation of Ocoxin®-Viusid® in Advanced Stomach Cancer and Gastric Esophagogastric Junction
Idiopathic Esophagogastric Junction Outflow Obstruction
Perioperative Combination Chemotherapy Versus Chemoradiation for Locally Advanced EGJ Adenocarcinoma
Severe Complications After Gastrectomy for Esophagogastric Junction and Gastric Cancer